1
|
Liang X, Yang Y, Huang C, Ye Z, Lai W, Luo J, Li X, Yi X, Fan JB, Wang Y, Wang Y. cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer. J Control Release 2023; 356:691-701. [PMID: 36933699 DOI: 10.1016/j.jconrel.2023.03.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Revised: 02/23/2023] [Accepted: 03/10/2023] [Indexed: 03/20/2023]
Abstract
Resistance to the chemotherapeutic agent cisplatin (DDP) is the primary reason for invalid chemotherapy of ovarian cancer. Given the complex mechanisms underlying chemo-resistance, the design of combination therapies based on blocking multiple mechanisms is a rationale to synergistically elevate therapeutic effect for effectively overcoming cancer chemo-resistance. Herein, we demonstrated a multifunctional nanoparticle (DDP-Ola@HR), which could simultaneously co-deliver DDP and Olaparib (Ola, DNA damage repair inhibitor) using targeted ligand cRGD peptide modified with heparin (HR) as nanocarrier, enabling the concurrent tackling of multiple resistance mechanisms to effectively inhibit the growth and metastasis of DDP-resistant ovarian cancer. In combination strategy, heparin could suppress the function of multidrug resistance-associated protein 2 (MRP2) and P-glycoprotein (P-gp) to promote the intracellular accumulation of DDP and Ola by specifically binding with heparanase (HPSE) to down-regulate PI3K/AKT/mTOR signaling pathway, and simultaneously served as a carrier combined with Ola to synergistically enhance the anti-proliferation ability of DDP for resistant ovarian cancer, thus achieving great therapeutic efficacy. Our DDP-Ola@HR could provide a simple and multifunctional combination strategy to trigger an anticipated cascading effect, thus effectively overcoming the chemo-resistance of ovarian cancer.
Collapse
Affiliation(s)
- Xiaomei Liang
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China
| | - Yulu Yang
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China
| | - Chuanqing Huang
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China
| | - Zhibin Ye
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China
| | - Wujiang Lai
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China
| | - Jiamao Luo
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China
| | - Xiaoxuan Li
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China
| | - Xiao Yi
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China
| | - Jun-Bing Fan
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China.
| | - Ying Wang
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China.
| | - Yifeng Wang
- Department of Obstetrics & Gynecology, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences; Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, Cuangdong, 510515, China.
| |
Collapse
|
2
|
Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2017; 82:291-298. [PMID: 29025661 DOI: 10.1016/j.msec.2017.07.051] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 06/28/2017] [Accepted: 07/29/2017] [Indexed: 12/23/2022]
Abstract
In this report, poly(amide amine) (PAMAM) dendrimer and Heparin-grafted-monomethoxy polyethylene glycol (HEP-mPEG) were synthesized and characterized. In aqueous solution, the generation 4 PAMAM dendrimers (G4.0-PAMAM) existed as nanoparticles with particle size of 5.63nm. However, after electrostatic complexation with HEP-mPEG to form a core@shell structure G4.0-PAMAM@HEP-mPEG, the size of nanoparticles was significantly increased (73.82nm). The G4.0-PAMAM@HEP-mPEG nanoparticles showed their ability to effectively encapsulate doxorubicin (DOX) for prolonged and controlled release. The cytocompatibility of G4.0-PAMAM@HEP-mPEG nanocarriers was significantly increased compared with its parentally G4.0-PAMAM dendrimer in both mouse fibroblast NIH3T3 and the human tumor HeLa cell lines. DOX was effectively encapsulated into G4.0-PAMAM@HEP-mPEG nanoparticles to form DOX-loaded nanocarriers (DOX/G4.0-PAMAM@HEP-mPEG) with high loading efficiency (73.2%). The release of DOX from DOX/G4.0-PAMAM@HEP-mPEG nanocarriers was controlled and prolonged up to 96h compared with less than 24h from their parentally G4.0-PAMAM nanocarriers. Importantly, the released DOX retained its bioactivity by inhibiting the proliferation of monolayer-cultured cancer HeLa cells with the same degree of fresh DOX. This prepared G4.0-PAMAM@HEP-mPEG nanocarrier can be a potential candidate for drug delivery systems with high loading capacity and low systemic toxicity in cancer therapy.
Collapse
|
3
|
Aron AT, Loehr MO, Bogena J, Chang CJ. An Endoperoxide Reactivity-Based FRET Probe for Ratiometric Fluorescence Imaging of Labile Iron Pools in Living Cells. J Am Chem Soc 2016; 138:14338-14346. [PMID: 27768321 PMCID: PMC5749882 DOI: 10.1021/jacs.6b08016] [Citation(s) in RCA: 187] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
![]()
Iron is essential for sustaining
life, as its ability to cycle
between multiple oxidation states is critical for catalyzing chemical
transformations in biological systems. However, without proper regulation,
this same redox capacity can trigger oxidative stress events that
contribute to aging along with diseases ranging from cancer to cardiovascular
and neurodegenerative disorders. Despite its importance, methods for
monitoring biological iron bound weakly to cellular ligands−the
labile iron pool−to generate a response that preserves spatial
and temporal information remain limited, owing to the potent fluorescence
quenching ability of iron. We report the design, synthesis, and biological
evaluation of FRET Iron Probe 1 (FIP-1), a reactivity-based probe
that enables ratiometric fluorescence imaging of labile iron pools
in living systems. Inspired by antimalarial natural products and related
therapeutics, FIP-1 links two fluorophores (fluorescein and Cy3) through
an Fe(II)-cleavable endoperoxide bridge, where Fe(II)-triggered peroxide
cleavage leads to a decrease in fluorescence resonance energy transfer
(FRET) from the fluorescein donor to Cy3 acceptor by splitting these
two dyes into separate fragments. FIP-1 responds to Fe(II) in aqueous
buffer with selectivity over competing metal ions and is capable of
detecting changes in labile iron pools within living cells with iron
supplementation and/or depletion. Moreover, application of FIP-1 to
a model of ferroptosis reveals a change in labile iron pools during
this form of cell death, providing a starting point to study iron
signaling in living systems.
Collapse
Affiliation(s)
- Allegra T Aron
- Department of Chemistry, ‡Department of Molecular and Cell Biology, and §Howard Hughes Medical Institute, University of California, Berkeley , Berkeley, California 94720, United States
| | - Morten O Loehr
- Department of Chemistry, ‡Department of Molecular and Cell Biology, and §Howard Hughes Medical Institute, University of California, Berkeley , Berkeley, California 94720, United States
| | - Jana Bogena
- Department of Chemistry, ‡Department of Molecular and Cell Biology, and §Howard Hughes Medical Institute, University of California, Berkeley , Berkeley, California 94720, United States
| | - Christopher J Chang
- Department of Chemistry, ‡Department of Molecular and Cell Biology, and §Howard Hughes Medical Institute, University of California, Berkeley , Berkeley, California 94720, United States
| |
Collapse
|
4
|
Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials 2013; 34:2252-64. [PMID: 23298778 DOI: 10.1016/j.biomaterials.2012.12.017] [Citation(s) in RCA: 186] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2012] [Accepted: 12/14/2012] [Indexed: 01/10/2023]
Abstract
Heparin drug conjugates are currently investigated as excellent candidates for drug delivery vehicles. In this study, we report the preparation and characterization of dendronized heparin-doxorubicin (heparin-DOX) conjugate as pH-sensitive drug delivery vehicle by combination of the features of dendrimer and heparin. Dynamic light scattering (DLS) and transmission electron microscope (TEM) studies demonstrated the dendronized heparin-DOX conjugate self-assembled into compact nanoparticles with negatively charged surface. The nanoparticles with 9.0 wt% (weight percent) of doxorubicin (DOX) showed pH-sensitive property due to the faster drug release rate at pH 5.0 and slow release rate at pH 7.4 aqueous. The nanoparticles were shown to effectively kill cancer cells in vitro. Notablely, the nanoparticles resulted in strong antitumor activity, high antiangiogenesis effects and induced apoptosis on the 4T1 breast tumor model due to the evidences from mice weight shifts, tumor weights, tumor growth curves, immunohistochemical assessment and histological analysis. It's also noteworthy that dendronized heparin and its nanoparticle with drug demonstrated no significant toxicity to healthy organs of both tumor-bearing and healthy mice, which was confirmed by histological analysis compared with free drug DOX. The dendronized heparin-DOX conjugate based nanopatilce with high antitumor activity and low side effects may be therefore a potential nanoscale drug delivery vehicle for breast cancer therapy.
Collapse
|
5
|
Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2012; 4:219-33. [PMID: 22231928 PMCID: PMC3288878 DOI: 10.1002/wnan.1157] [Citation(s) in RCA: 281] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Modifying surfaces of nanoparticles (NPs) with polyethylene glycol (PEG), the so-called PEGylation, is the most commonly used method for reducing premature clearance of NPs from the circulation. However, several reports point out that PEGylation may negatively influence the performance of NPs as a drug carrier. Alternative surface modification strategies, including substitute polymers, conditional removal of PEG, and biomimetic surface modification, may provide solutions for the limitations of PEG.
Collapse
Affiliation(s)
- Zohreh Amoozgar
- Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA
| | - Yoon Yeo
- Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA
| |
Collapse
|
6
|
Wang Y, Wang Y, Xiang J, Yao K. Target-Specific Cellular Uptake of Taxol-Loaded Heparin-PEG-Folate Nanoparticles. Biomacromolecules 2010; 11:3531-8. [DOI: 10.1021/bm101013s] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Ying Wang
- Cancer Research Institute, Southern Medical University, Guangzhou, 510515, China, Departments of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, United States, and Biomedical Engineering Center, College of Chemistry and Chemical Engineering, and State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, 410082, China
| | - Yiqing Wang
- Cancer Research Institute, Southern Medical University, Guangzhou, 510515, China, Departments of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, United States, and Biomedical Engineering Center, College of Chemistry and Chemical Engineering, and State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, 410082, China
| | - Jiannan Xiang
- Cancer Research Institute, Southern Medical University, Guangzhou, 510515, China, Departments of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, United States, and Biomedical Engineering Center, College of Chemistry and Chemical Engineering, and State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, 410082, China
| | - Kaitai Yao
- Cancer Research Institute, Southern Medical University, Guangzhou, 510515, China, Departments of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, United States, and Biomedical Engineering Center, College of Chemistry and Chemical Engineering, and State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, 410082, China
| |
Collapse
|
7
|
Wang Y, Xin D, Liu K, Zhu M, Xiang J. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 2010; 20:2214-21. [PMID: 19950889 DOI: 10.1021/bc8003809] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We have synthesized a series of novel prodrugs consisting of amphiphilic heparin-paclitaxel conjugates. Each prodrug in the series consists of a succinylated-heparin carrier conjugated to paclitaxel via a single amino acid spacer, either valine, leucine, or phenylalanine (prodrug1, prodrug2, and prodrug3, respectively). Unlike physically encapsulated drugs, these prodrugs can self-assemble to form nanoparticles in aqueous solution while still maintaining structural integrity for loading parent drug due to the dual hydrophilic/hydrophobic nature of the carrier and drug compound. The structure of prodrugs has been characterized by 1H NMR, FT-IR, and GPC. Their morphology has been investigated by SEM. Our results show that these self-assembled nanoparticles have a narrow size distribution (140-180 nm) and form an approximately spherical shape composed of a paclitaxel core and carrier shell. The anticoagulant activity of all the prodrugs is sharply decreased compared to that of heparin, as measured by activated partial thromboplastin time (aPTT), thereby reducing the risk of severe hemorrhagic complication during systemic administration. Furthermore, the prodrugs exhibit better in vitro cell inhibition for MCF-7 cells than free paclitaxel. Flow cytometric analyses (FCM) have shown that MCF-7 cells treated with prodrugs are arrested in the G(2)/M phase of the cell cycle. Meanwhile, these three prodrugs each exhibit unique hydrolysis properties under various physiological or plasma conditions. In particular, prodrug2 with leucine spacer may result in favorable hydrolysis of the ester bond between the amino acid and paclitaxel under physiological conditions. In mice, prodrug2 shows a similar ovarian tumor growth inhibition as paclitaxel and induces no obvious body weight loss. Hence, the prepared nanoscale prodrugs are expected not only to render structural integrity to the parent drug, but also enhance targeting capacity to solid tumors.
Collapse
Affiliation(s)
- Ying Wang
- Biomedical Engineering Center, College of Chemistry and Chemical Engineering, and State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha 410082, China
| | | | | | | | | |
Collapse
|